Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-8f36194c6cc063f159cffcece33902d5"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-8f36194c6cc063f159cffcece33902d5"/>
<resource>
<Composition>
<id value="composition-en-8f36194c6cc063f159cffcece33902d5"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-8f36194c6cc063f159cffcece33902d5"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-8f36194c6cc063f159cffcece33902d5</b></p><a name="composition-en-8f36194c6cc063f159cffcece33902d5"> </a><a name="hccomposition-en-8f36194c6cc063f159cffcece33902d5"> </a><a name="composition-en-8f36194c6cc063f159cffcece33902d5-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/02/240/001 10 mg 30 vials</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - somavert</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/02/240/001 10 mg 30 vials"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp8f36194c6cc063f159cffcece33902d5"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - somavert"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What SOMAVERT is and what it is used for</li><li>What you need to know before you use SOMAVERT</li><li>How to use SOMAVERT</li><li>Possible side effects</li><li>How to store SOMAVERT</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What somavert is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What somavert is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>SOMAVERT is used for the treatment of acromegaly, a hormonal disorder resulting from the increased secretion of growth hormone (GH) and IGF-I (Insulin-like growth factors), which is characterised by overgrowth of bone, soft tissue swelling, heart disease and related disorders. The active substance in SOMAVERT, pegvisomant is known as a growth hormone receptor antagonist. These substances decrease the action of GH and levels of IGF-I circulating in the blood.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take somavert"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text
value="2. What you need to know before you take somavert"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not use SOMAVERT</p><h2 id="if-you-are-allergic-to-pegvisomant-or-any-of-the-other-ingredients-of-this-medicine-listed-in-section-6-warnings-and-precautions-talk-to-your-doctor-pharmacist-or-nurse-before-using-somavert">If you are allergic to pegvisomant or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Talk to your doctor, pharmacist or nurse before using SOMAVERT.</h2><h2 id="if-you-experience-disturbed-vision-or-headaches-you-must-contact-your-doctor-immediately">If you experience disturbed vision or headaches you must contact your doctor immediately.</h2><h2 id="your-doctor-or-nurse-will-monitor-the-levels-of-igf-i-insulin-like-growth-factors-circulating-in-the-blood-and-adjust-the-dose-of-somavert-if-necessary">Your doctor or nurse will monitor the levels of IGF-I (Insulin-like growth factors) circulating in the blood and adjust the dose of SOMAVERT if necessary.</h2><h2 id="your-doctor-should-also-monitor-your-adenoma-benign-tumour">Your doctor should also monitor your adenoma (benign tumour).</h2><h2 id="your-doctor-will-conduct-tests-of-your-liver-function-before-starting-and-during-treatment-with-somavert-if-these-test-results-are-not-normal-your-doctor-will-discuss-treatment-options-with-you-once-treatment-begins-your-doctor-or-nurse-will-monitor-the-level-of-liver-enzymes-in-the-blood-every-4-6-weeks-for-the-first-6-months-of-treatment-with-somavert-administration-of-somavert-should-be-discontinued-if-signs-of-liver-disease-persist">Your doctor will conduct tests of your liver function before starting and during treatment with SOMAVERT. If these test results are not normal, your doctor will discuss treatment options with you. Once treatment begins, your doctor or nurse will monitor the level of liver enzymes in the blood every 4-6 weeks for the first 6 months of treatment with SOMAVERT. Administration of SOMAVERT should be discontinued if signs of liver disease persist.</h2><h2 id="if-you-are-diabetic-your-doctor-may-need-to-adjust-the-amount-of-insulin-or-other-medicines-you-are-using">If you are diabetic, your doctor may need to adjust the amount of insulin or other medicines you are using.</h2><p>Fertility in women patients may be increased as the disease improves. The use of this medicine in pregnant women is not recommended and women of childbearing age should be advised to use a contraception. See also the section about Pregnancy below. Other medicines and SOMAVERT You must tell your doctor if you have previously used other medicines for the treatment of acromegaly or medicines for the treatment of diabetes. Tell your doctor or pharmacist if you are using or have recently used any other medicines. As part of your treatment you may be given other medicines. It is important to keep using all your medicines as well as SOMAVERT unless you are told otherwise by your doctor, pharmacist or nurse. Pregnancy, breast-feeding and fertility The use of SOMAVERT in pregnant women is not recommended. If you are a women of childbearing age, a contraception should be used during treatment. It is not known if pegvisomant passes into breast milk. You should not breast-feed while taking SOMAVERT unless your doctor has discussed this with you. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Driving and using machines No studies on the effects on the ability to drive and use machines have been performed. SOMAVERT contains sodium This medicine contains less than 1 mmol of sodium (23 mg) per dose i.e. essentially sodium-free .</p></div>
</text>
</section>
<section>
<title value="3. How to take somavert"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take somavert"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always inject this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. A starting dose of 80 mg of pegvisomant will be given subcutaneously (just under the skin) by your doctor. Following this, the usual daily dose of pegvisomant is 10 mg, which is given by subcutaneous injection (just under the skin). Every four to six weeks your doctor will make appropriate dose adjustments, made in increments of 5 mg pegvisomant/day, based on your so-called serum IGF-I levels to maintain an optimal therapeutic response. Method and route of administration SOMAVERT is injected under the skin. The injection can be self-administered or given by another person, for example your doctor or his/her assistant. The detailed instructions on injection procedure provided at the end of this leaflet must be followed. You should continue to inject this medicine for as long as instructed by your doctor. This medicine must be dissolved before use. The injection must not be mixed in the same syringe or vial as any other medicine. Fatty tissue of the skin can build-up at the site of injection. To avoid this, use a slightly different place for your injection each time, as described in Step 2 of the instructions for preparing and giving an injection of SOMAVERT section of this leaflet. This gives your skin and the area under your skin time to recover from one injection before it receives another one in the same place. If you have the impression that the effect of this medicine is too strong or too weak, talk to your doctor, pharmacist or nurse. If you inject more SOMAVERT than you should If you accidentally inject more SOMAVERT than told to by your doctor it is unlikely to be serious, but you should contact your doctor, pharmacist or nurse immediately. If you forget to use SOMAVERT If you forget to give yourself an injection you should inject the next dose as soon as you remember and then continue to inject SOMAVERT as prescribed by your doctor. Do not inject a double dose to make up for forgotten individual doses. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Mild to serious allergic (anaphylactic) reactions have been reported in some patients taking SOMAVERT. Symptoms of a serious allergic reaction may include one or more of the following: swelling of the face, tongue, lips, or throat; wheezing or trouble breathing (spasm of the larynx); generalised skin rash, nettle rash (urticaria) or itching; or dizziness. Contact your doctor immediately if you develop any of these symptoms. Very common may affect more than 1 in 10 people:</p><p>Headache</p><p>Diarrhoea</p><p>Joint pain Common: may affect up to 1 in 10 people</p><p>Shortness of breath.</p><p>Increased levels of substances that measure the function of the liver. These can be seen in the results of blood tests.</p><p>Blood in the urine.</p><p>Increased blood pressure.</p><p>Constipation, feeling sick, being sick, feeling bloated, indigestion, gas.</p><p>Dizziness, sleepiness, uncontrolled trembling, decreased sense of touch.</p><p>Bruising or bleeding at injection site, soreness or swelling at injection site, build-up of fat below the surface of the skin at injection site, swelling of the extremities, weakness, fever.</p><p>Sweating, itching, rash, tendency to bruise.</p><p>Muscle pain, arthritis.</p><p>Increased blood cholesterol, weight gain, increased blood glucose, decreased blood glucose.</p><p>Flu-like illness, fatigue.</p><p>Abnormal dreams.</p><p>Eye pain Uncommon: may affect up to 1 in 100 people</p><p>Allergic reaction after administration (fever, rash, pruritus and, in severe cases, difficulty to breathe, rapid swelling of skin, requiring urgent medical attention). May occur immediately, or several days after administration.</p><p>Protein in the urine, increased urine, kidney problems.</p><p>Lack of interest, feeling confused, increased sex drive, panic attack, loss of memory, problems sleeping.</p><p>Decreased platelets in the blood, increased or decreased white cells in the blood, tendency to bleed.</p><p>Feeling abnormal, impaired healing.</p><p>Eyestrain, inner ear problems.</p><p>Facial swelling, dry skin, night sweats, redness of the skin (erythema), raised itchy bumps on the skin (urticaria).</p><p>Increased fatty substances in the blood, increased appetite.</p><p>Dry mouth, increased saliva, tooth problems, haemorrhoids.</p><p>Abnormal sense of taste, migraine. Not known: frequency cannot be estimated from the available data</p><p>Anger</p><p>Severe breathlessness (laryngospasm)</p><p>Rapid swelling of skin and underlying tissue and inner lining (mucosa) of organs (angioedema) About 17% of patients will develop antibodies to growth hormone during treatment. The antibodies do not seem to stop this medicine from working. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store somavert"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store somavert"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the vial and the carton after EXP. The expiry date refers to the last day of that month. Store the powder vial(s) in a refrigerator (2 C 8 C) in their carton(s) in order to protect from light. Do not freeze. The carton(s) containing the SOMAVERT powder vial(s) may be stored at room temperature up to a maximum of 25 C for a single period of up to 30 days. Write the Use by date on the carton including day/month/year (up to 30 days from the date removed from the refrigerator). The vial(s) must be protected from light. Do not return this medicine to refrigerator. Discard this medicine if not used by the new Use by date or the expiry date printed on the carton, whichever is earlier. Store the pre-filled syringe(s) below 30 C or store in a refrigerator (2 C 8 C). Do not freeze. After preparing the SOMAVERT solution it must be used immediately. Do not use this medicine if you notice that the solution is cloudy or contains particulate matter. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><h2 id="what-somavert-contains">What SOMAVERT contains</h2><h2 id="the-active-substance-is-pegvisomant">The active substance is pegvisomant.</h2><h2 id="somavert-10-mg-one-vial-of-powder-contains-10-mg-pegvisomant-after-reconstitution-with-1-ml-of-solvent-1-ml-of-the-solution-contains-10-mg-pegvisomant">SOMAVERT 10 mg: One vial of powder contains 10 mg pegvisomant. After reconstitution with 1 ml of solvent, 1 ml of the solution contains 10 mg pegvisomant.</h2><h2 id="somavert-15-mg-one-vial-of-powder-contains-15-mg-pegvisomant-after-reconstitution-with-1-ml-of-solvent-1-ml-of-the-solution-contains-15-mg-pegvisomant">SOMAVERT 15 mg: One vial of powder contains 15 mg pegvisomant. After reconstitution with 1 ml of solvent, 1 ml of the solution contains 15 mg pegvisomant.</h2><h2 id="somavert-20-mg-one-vial-of-powder-contains-20-mg-pegvisomant-after-reconstitution-with-1-ml-of-solvent-1-ml-of-the-solution-contains-20-mg-pegvisomant">SOMAVERT 20 mg: One vial of powder contains 20 mg pegvisomant. After reconstitution with 1 ml of solvent, 1 ml of the solution contains 20 mg pegvisomant.</h2><h2 id="somavert-25-mg-one-vial-of-powder-contains-25-mg-pegvisomant-after-reconstitution-with-1-ml-of-solvent-1-ml-of-the-solution-contains-25-mg-pegvisomant">SOMAVERT 25 mg: One vial of powder contains 25 mg pegvisomant. After reconstitution with 1 ml of solvent, 1 ml of the solution contains 25 mg pegvisomant.</h2><h2 id="somavert-30-mg-one-vial-of-powder-contains-30-mg-pegvisomant-after-reconstitution-with-1-ml-of-solvent-1-ml-of-the-solution-contains-30-mg-pegvisomant">SOMAVERT 30 mg: One vial of powder contains 30 mg pegvisomant. After reconstitution with 1 ml of solvent, 1 ml of the solution contains 30 mg pegvisomant.</h2><h2 id="the-other-ingredients-are-glycine-mannitol-e421-disodium-phosphate-anhydrous-and-sodium-dihydrogen-phosphate-monohydrate-see-section-2-somavert-contains-sodium-">The other ingredients are glycine, mannitol (E421), disodium phosphate anhydrous and sodium dihydrogen phosphate monohydrate (see section 2 SOMAVERT contains sodium ).</h2><p>The solvent is water for injections. What SOMAVERT looks like and contents of the pack SOMAVERT is presented as a powder and a solvent for injection (either 10 mg, 15 mg, 20 mg, 25 mg or 30 mg pegvisomant in a vial and 1 ml of solvent in a pre-filled syringe). Pack sizes of 1 and/or 30. Not all pack sizes are marketed. The powder is white and the solvent is clear and colourless. Marketing Authorisation Holder and Manufacturer: Marketing Authorisation Holder: Pfizer Europe MA EEIG Boulevard de la Plaine 1050 Bruxelles Belgium Manufacturer: Pfizer Manufacturing Belgium NV Rijksweg 2870 Puurs-Sint-Amands Belgium For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder. Belgi /Belgique/Belgien Luxembourg/Luxemburg Pfizer NV/SA T l/Tel: +32 (0)2 554 62 Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel: +370 5 251 4 ,<br/>.: +359 2 970 4Magyarorsz g Pfizer Kft. Tel.: + 36 1 488 37 esk republika Pfizer, spol. s r.o. Tel: +420 283 004 Malta Vivian Corporation Ltd. Tel: +356 21344Danmark Pfizer ApS Tlf: +45 44 20 11 Nederland Pfizer bv Tel: +31 (0)800 63 34 Deutschland PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51Norge Pfizer AS Tlf: +47 67 52 61 Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7 sterreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0</p><h2 id="pfizer----30-210-6785polska-pfizer-polska-sp-z-oo-tel-48-22-335-61-espa-a-pfizer-sl-tel-34-91-490-99-portugal-laborat-rios-pfizer-lda-tel-351-21-423-5france-pfizer-t-l-33-01-58-07-34-rom-nia-pfizer-romania-srl-tel-40-0-21-207-28-hrvatska-pfizer-croatia-doo-tel--385-1-3908-slovenija-pfizer-luxembourg-sarl-pfizer-podru-nica-za-svetovanje-s-podro-ja-farmacevtske-dejavnosti-ljubljana-tel-386-01-52-11-ireland-pfizer-healthcare-ireland-tel-1800-633-363-toll-free-tel-44-01304-616slovensk-republika-pfizer-luxembourg-sarl-organiza-n-zlo-ka-tel--421-2-3355-5-sland-icepharma-hf-s-mi-354-540-8suomifinland-pfizer-oy-puhtel-358-09-430-italia-pfizer-srl-tel-39-06-33-18-sverige-pfizer-ab-tel-46-08-550-520-pfizer---cyprus-branch--357-22817united-kingdom-northern-ireland-pfizer-limited-tel-44-01304-616latvija-pfizer-luxembourg-sarl-fili-le-latvij-tel--371-670-35-this-leaflet-was-last-revised-in-mmyyyy-other-sources-of-information-detailed-information-on-this-medicine-is-available-on-the-european-medicines-agency-web-site-httpwwwemaeuropaeu-there-are-also-links-to-other-websites-about-rare-diseases-and-treatments">Pfizer . . : +30 210 6785Polska Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 Espa a Pfizer, S.L. Tel: +34 91 490 99 Portugal Laborat rios Pfizer, Lda. Tel: +351 21 423 5France Pfizer T l: +33 (0)1 58 07 34 Rom nia Pfizer Romania S.R.L. Tel: +40 (0) 21 207 28 Hrvatska Pfizer Croatia d.o.o. Tel: + 385 1 3908 Slovenija Pfizer Luxembourg SARL Pfizer, podru nica za svetovanje s podro ja farmacevtske dejavnosti, Ljubljana Tel: +386 (0)1 52 11 Ireland Pfizer Healthcare Ireland Tel: 1800 633 363 (toll free) Tel: +44 (0)1304 616Slovensk republika Pfizer Luxembourg SARL, organiza n zlo ka Tel: + 421 2 3355 5 sland Icepharma hf. S mi: +354 540 8Suomi/Finland Pfizer Oy Puh/Tel: +358 (0)9 430 Italia Pfizer S.r.l. Tel: +39 06 33 18 Sverige Pfizer AB Tel: +46 (0)8 550 520<br/>Pfizer . . (Cyprus Branch) : +357 22817United Kingdom (Northern Ireland) Pfizer Limited Tel: +44 (0)1304 616Latvija Pfizer Luxembourg SARL fili le Latvij Tel: + 371 670 35 This leaflet was last revised in <{MM/YYYY}>. Other sources of information Detailed information on this medicine is available on the European Medicines Agency web site: <a href="http://www.ema.europa.eu">http://www.ema.europa.eu</a>. There are also links to other websites about rare diseases and treatments.</h2><p>INSTRUCTIONS FOR USE SOMAVERT powder in vial with solvent in a pre-filled syringe pegvisomant for injection For Subcutaneous Injection Only single dose vial SOMAVERT comes in a vial as a white block of powder. You must mix SOMAVERT with a liquid (diluent) before you can use it. The liquid comes in a pre-filled syringe labeled Solvent for SOMAVERT . Do not use any other liquid to mix with SOMAVERT. It is important that you do not try to give yourself or someone else an injection unless you have received training from your healthcare provider. Store the carton(s) of powder vials in the refrigerator at 2 C to 8 C and away from direct sunlight. The carton(s) containing the SOMAVERT powder vial(s) may be stored at room temperature up to a maximum of 25 C for a single period of up to 30 days. Write the Use by date on the carton including day/month/year (up to 30 days from the date removed from the refrigerator). The vial(s) must be protected from light. Do not return this medicine to refrigerator. Discard this medicine if not used by the new Use by date or the expiry date printed on the carton, whichever is earlier. The pre-filled solvent syringe may be stored at room temperature. Keep out of reach of children.</p><ol type="1"><li>Things you need A single SOMAVERT pack containing:</li></ol><p>A vial of SOMAVERT powder.</p><p>A pre-filled syringe with solvent.</p><p>A safety needle. You will also need:</p><p>A cotton ball.</p><p>An alcohol swab.</p><p>A suitable sharps container. 2. Getting ready Before you start:</p><p>Only mix SOMAVERT and the solvent when you are ready to inject your dose.</p><p>Remove a single SOMAVERT pack from the refrigerator and allow it to come to room temperature naturally in a safe place.</p><p>Wash your hands with soap and water, and dry thoroughly.</p><p>Peel open the packaging of the syringe and safety needle to make it easier to pick up each item as you prepare for your injection.</p><p>Do not use the syringe or vial if: * they are damaged or faulty; * the expiration date has passed; * it has been frozen, even if it has now thawed (syringe only). 3. Choose injection area</p><p>Choose a different location within an area for each injection.</p><p>Avoid bony areas or areas that are bruised, red, sore or hard, or areas that have scars or skin conditions.</p><p>Clean the injection area with the alcohol swab as instructed by your healthcare provider.</p><p>Allow the injection area to dry. 4. Remove vial cap</p><p>Remove the cap from the vial.</p><p>Throw the cap away; it is not needed again. Caution: Do not let anything touch the vial stopper. 5. Remove syringe cap</p><p>Snap off the syringe cap. It may take more effort to snap off than you might expect.</p><p>Throw the syringe cap away; it is not needed again.</p><p>Keep the syringe upright to avoid leakage. Caution: Do not let the end of the syringe touch anything when the syringe cap is off. 6. Attach safety needle</p><p>Twist the safety needle firmly onto the syringe as far as it will go. 7. Remove needle cover</p><p>Fold the needle guard out of the way of the needle cover.</p><p>Carefully pull the needle cover straight off.</p><p>Throw the needle cover away; it is not needed again. Caution: Do not let the needle touch anything. 8. Insert needle</p><p>Push the needle through the centre of vial stopper, as shown.</p><p>Support the syringe while the needle is in the vial stopper to prevent bending the needle. 9. Add liquid</p><p>Tilt both the vial and syringe at an angle, as shown.</p><p>Push the plunger rod down slowly until all the liquid has emptied into the vial.</p><p>Caution: Do not squirt the liquid directly onto the powder, as this creates foam. Foam makes the medicine unusable.</p><p>Do not withdraw the needle yet. 10. Swirl vial</p><p>Support both the syringe and vial in one hand, as shown.</p><p>Gently swirl the liquid, sliding the vial in a circular motion on a flat surface.</p><p>Continue swirling the liquid until all the powder has fully dissolved. Note: This may take up to 5 minutes. 11. Check medicine</p><p>Keeping the needle in the vial, look carefully at the medicine. It must be clear and free of particles.</p><p>Do not use if:* the medicine is cloudy or hazy;* the medicine has any colour at all;* there are any particles or there is a layer of foam in the vial. 12. Reposition needle</p><p>Turn the vial so that you can see the stopper gap, as shown.</p><p>Pull the needle down so that the needle tip is at the lowest point in the liquid. This will help you to draw off as much liquid as possible.</p><p>Check that the plunger rod has not moved if it has, then push it back all the way into the syringe. This ensures that all air is removed from the syringe before you draw off the dose. 13. Draw off dose</p><p>Slowly pull back the plunger rod to withdraw as much medicine as possible from the vial. Note: If you see air in the syringe, tap the barrel to float the bubbles to the top, and then gently push the bubbles out into the vial.</p><p>Pull the needle out of the vial. 14. Insert needle</p><p>Gently pinch the skin at the site of injection.</p><p>Insert the needle to its full depth into the pinched skin. 15. Inject medicine</p><p>Push the plunger rod down slowly until the barrel is empty. Note: Make sure you keep the needle in at full depth.</p><p>Release the pinched skin and pull the needle straight out. 16. Make needle safe</p><p>Fold the needle guard over the needle.</p><p>Gently apply pressure using a hard surface to lock the needle guard in place. Note: You will hear a click when the needle guard has been locked. 17. Dispose</p><p>The syringe and needle should NEVER be reused. Dispose of the needle and syringe as instructed by your doctor, nurse or pharmacist and in accordance with local health and safety laws. 18. After injection</p><p>If necessary, use a clean cotton ball and press lightly on the injection area.</p><p>Do not rub the area. QUESTIONS & ANSWERS What should I do if anything has accidentally touched the vial stopper?</p><p>Clean the vial stopper with a fresh alcohol wipe, and leave it to dry completely. If you are unable to clean the stopper, do not use the vial. What should I do with the syringe if it has been dropped?</p><p>Do not use it even if it looks undamaged. Dispose of the syringe in the same way as a used syringe. You will need a replacement syringe. How many times can I safely insert the needle into the vial stopper?</p><p>Once only. Withdrawing and reinserting greatly increases the risk of needle damage, and will blunt the needle. This can cause discomfort and increases risk of skin damage and infection. There is also a risk you may lose some of the medicine. Is it OK to shake the vial if the powder is not dissolving?</p><p>No never shake the vial. Shaking can destroy the medicine and create foam. The powder may take a few minutes to dissolve fully, so continue swirling the vial gently until the liquid is completely clear. How can I tell if there is any foam in the vial?</p><p>Foam looks like a mass of small bubbles that float as a layer to the top of the liquid. Do not inject SOMAVERT if it has foamed. How can I prevent the medicine from foaming?</p><p>Press the plunger very slowly so that the liquid gently runs down the inside of the vial. Do not spray the liquid directly onto the powder, as this creates foam. This technique will also reduce the swirling time and allow more of the medicine to be drawn off. I can see some air in the syringe. Is this OK?</p><p>Tiny air bubbles in the liquid are normal and are safe to inject. However, it is possible to accidently draw air into the syringe, which should be removed before injecting. Bubbles or air gaps that float to the top of the liquid should be pushed back out into the vial. Why can t I get all of the medicine out of the vial?</p><p>The shape of the vial means that a very small amount of the medicine will be left behind in the vial. This is normal. To ensure that only a trace of medicine remains, make sure the needle tip is as low as it can be in the vial when drawing off your dose. What should I do if I have any doubts about my medicine?</p><p>All questions should be handled by a doctor, nurse or pharmacist familiar with SOMAVERT.</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp8f36194c6cc063f159cffcece33902d5"/>
<resource>
<MedicinalProductDefinition>
<id value="mp8f36194c6cc063f159cffcece33902d5"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp8f36194c6cc063f159cffcece33902d5"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp8f36194c6cc063f159cffcece33902d5</b></p><a name="mp8f36194c6cc063f159cffcece33902d5"> </a><a name="hcmp8f36194c6cc063f159cffcece33902d5"> </a><a name="mp8f36194c6cc063f159cffcece33902d5-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/02/240/001 10 mg 30 vials</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: SOMAVERT 10 mg powder and solvent for solution for injection</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/02/240/001 10 mg 30 vials"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName
value="SOMAVERT 10 mg powder and solvent for solution for injection"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
